Mechanistic insights into benzoxaborole activity against Cryptosporidium parvum: CPSF3 targeting genetically validated for AN3661, with implications for resistance

Background Cryptosporidiosis is a major enteric disease affecting humans and animals worldwide, with severe consequences in young children and neonatal livestock, yet treatment options remain extremely limited. Benzoxaboroles have emerged as promising broad-spectrum antiparasitic compounds, but their mechanisms of action, molecular targets, and resistance pathways in Cryptosporidium spp. remain incompletely understood, limiting their optimal therapeutic deployment. We previously showed that the benzoxaborole AN3661 inhibits the endonuclease Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) in Cryptosporidium hominis , likely by disrupting pre-mRNA processing and restricting parasite growth. Here, we further investigated the mode of action of AN3661 and compared it with two additional benzoxaboroles, AN13762 and AN7973. Methodology Cell culture assays combined with imaging-based quantification were used to assess drug activity and determine the impact of treatment on parasite growth and development. CRISPR-Cas9 genome editing was used to introduce a point mutation into Cryptosporidium parvum CPSF3 and evaluate resistance to benzoxaboroles in vitro and in vivo . Nanopore sequencing was performed to examine the effects of drug exposure on parasite mRNA processing. Principal Findings We identified a single mutation in C. parvum CPSF3 (Y385N) that conferred strong resistance to AN3661. In contrast, this mutation did not reduce sensitivity to AN13762 or AN7973, which are also suspected to target CPSF3. All three benzoxaboroles impaired mRNA processing, a process mediated by the CPSF machinery, and exhibited parasiticidal activity, with pronounced effects during late-stage maturation of first-generation meronts, including inhibition of parasite egress; two compounds also affected gametogenesis. Notably, AN7973 controlled severe infection in susceptible mice challenged with the AN3661-resistant C. parvum CPSF3 Y385N mutant. In Toxoplasma gondii , AN7973 remained active against strains resistant to AN3661 and AN13762, supporting a distinct mechanism of action. Finally, AN3661 and AN7973 were active against Eimeria tenella, and AN3661 against Giardia duodenalis . Conclusions/Significance Together, these results identify a resistance mechanism affecting AN3661 in Cryptosporidium , and highlight AN7973 as a promising alternative compound with broad antiparasitic activity and efficacy against AN3661-resistant parasites.

Authors

Institutions

Publication Details

Journal
PLoS neglected tropical diseases
Published
2026-11-18
DOI
https://doi.org/10.1371/journal.pntd.0014883
Primary Topic
Parasitic Infections and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Mechanistic insights into benzoxaborole activity against Cryptosporidium parvum: CPSF3 targeting genetically validated for AN3661, with implications for resistance

Christopher Swale, Irina Dobrescu, Fabrice Laurent, Marco Lalle et al.
2 links
PLoS neglected tropical diseases
Parasitic Infections and Diagnostics
article

Mechanistic insights into benzoxaborole activity against Cryptosporidium parvum: CPSF3 targeting genetically validated for AN3661, with implications for resistance

Christopher Swale, Irina Dobrescu, Fabrice Laurent, Marco Lalle, Mohamed‐Ali Hakimi, Laurence Braun, Alexandre Bougdour, Julien Pichon, Janine Wenker, Thomas Baty
article en

Abstract

Background Cryptosporidiosis is a major enteric disease affecting humans and animals worldwide, with severe consequences in young children and neonatal livestock, yet treatment options remain extremely limited. Benzoxaboroles have emerged as promising broad-spectrum antiparasitic compounds, but their mechanisms of action, molecular targets, and resistance pathways in Cryptosporidium spp. remain incompletely understood, limiting their optimal therapeutic deployment. We previously showed that the benzoxaborole AN3661 inhibits the endonuclease Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) in Cryptosporidium hominis , likely by disrupting pre-mRNA processing and restricting parasite growth. Here, we further investigated the mode of action of AN3661 and compared it with two additional benzoxaboroles, AN13762 and AN7973. Methodology Cell culture assays combined with imaging-based quantification were used to assess drug activity and determine the impact of treatment on parasite growth and development. CRISPR-Cas9 genome editing was used to introduce a point mutation into Cryptosporidium parvum CPSF3 and evaluate resistance to benzoxaboroles in vitro and in vivo . Nanopore sequencing was performed to examine the effects of drug exposure on parasite mRNA processing. Principal Findings We identified a single mutation in C. parvum CPSF3 (Y385N) that conferred strong resistance to AN3661. In contrast, this mutation did not reduce sensitivity to AN13762 or AN7973, which are also suspected to target CPSF3. All three benzoxaboroles impaired mRNA processing, a process mediated by the CPSF machinery, and exhibited parasiticidal activity, with pronounced effects during late-stage maturation of first-generation meronts, including inhibition of parasite egress; two compounds also affected gametogenesis. Notably, AN7973 controlled severe infection in susceptible mice challenged with the AN3661-resistant C. parvum CPSF3 Y385N mutant. In Toxoplasma gondii , AN7973 remained active against strains resistant to AN3661 and AN13762, supporting a distinct mechanism of action. Finally, AN3661 and AN7973 were active against Eimeria tenella, and AN3661 against Giardia duodenalis . Conclusions/Significance Together, these results identify a resistance mechanism affecting AN3661 in Cryptosporidium , and highlight AN7973 as a promising alternative compound with broad antiparasitic activity and efficacy against AN3661-resistant parasites.

PLoS neglected tropical diseasesVol. 20(11)
Université de Tours (FR), Inserm (FR), Istituto Superiore di Sanità (IT), Institut National de la Recherche Scientifique (CA), Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR), Services déconcentrés d'appui à la recherche Pays de la Loire (FR), Infectiologie et santé publique (FR), Institut National de la Recherche Agronomique (FR), Université Grenoble Alpes (FR)
Alliance Française contre les Maladies Parasitaires, European Commission, Agence Nationale de la Recherche, Université François-Rabelais, HORIZON EUROPE Framework Programme
Good health and well-being
Parasitic Infections and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon